A5071863854- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Viral-associated cancers and disorders
- Transplantation: Methods and Outcomes
- Polyomavirus and related diseases
- Mesenchymal stem cell research
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Cancer-related molecular mechanisms research
- Cytomegalovirus and herpesvirus research
- Water Quality Monitoring Technologies
- T-cell and B-cell Immunology
- Histone Deacetylase Inhibitors Research
- Immune Response and Inflammation
- Industrial Technology and Control Systems
- RNA modifications and cancer
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Acute Lymphoblastic Leukemia research
- Cytokine Signaling Pathways and Interactions
- Hematological disorders and diagnostics
- Single-cell and spatial transcriptomics
- Water Quality Monitoring and Analysis
- Chronic Myeloid Leukemia Treatments
Anhui Provincial Hospital
2010-2023
Anhui Medical University
2010-2017
Although classic Hodgkin lymphoma (cHL) is highly curable with current treatment paradigms, therapy fails in 10-25% of patients. This prospective multicenter phase II study attempted to investigate the efficacy and safety combination tislelizumab gemcitabine oxaliplatin (T-GemOx) relapsed or refractory cHL. Participants received six eight courses (1 g/m2 on day 1) (100 mg/m2 combined (200 mg 2) at 21-day intervals, followed by maintenance (every 2 months for years). The main outcome measure...
It has been established that Cutaneous T-Cell lymphomas (CTCL) are caused by the monoclonal proliferation of T lymphocytes in skin. This heterogeneous group diseases represents a significant source distress to patients since diagnosis and treatment often challenging. As one most abundant internal modifications mRNA higher eukaryotes, N6-methyladenosine (m6A) is widely recognized affect development progression cancers. However, knowledge on involvement m6A CTCL still limited. In this work, we...
The European Group for Blood and Marrow Transplantation (EBMT) risk score has been implemented as an important tool to predict patient outcomes after allogeneic hematopoietic stem cell transplantation. However, our knowledge, this never applied in cases of single umbilical cord blood transplantation (sUCBT). We retrospectively analyzed 207 consecutive patients with acute leukemia who received sUCBT at center between February 2011 December 2015. probabilities 3-year overall survival (OS)...
To the editor: Non-Hodgkin lymphoma (NHL) is a common type of hematological malignancy. Although development targeted therapies has improved survival patients with aggressive NHL, autologous hematopoietic stem cell transplantation (HSCT) remains indispensable. There no standard conditioning regimen for (ASCT). Three regimens are carmustine, etoposide, cytarabine, and melphalan (BEAM); cyclophosphamide (BEAC); total body irradiation. The 3-year progression-free-survival (PFS) rate associated...
Abstract Background : The tumor immune microenvironment (TIME) is crucial for follicular lymphoma (FL) pathogenesis and progression. However, TIME evolution during progression of disease within 24 months (POD24) unknown. Methods: Spatially-resolved single-cell image mass cytometry with a panel 36 meta-tagged antibodies was quantitatively used to dissect the structure in 13 paired FLs at diagnosis POD24. Results: Increased CD163 − macrophages PD-1 ligand upregulation decreased CD8 + T cells...